|
TMCO3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
8.08889999426299E-09 |
| Normal-vs-Stage3 |
8.19377898864104E-12 |
| Normal-vs-Stage4 |
8.84510020782159E-10 |
| Stage1-vs-Stage2 |
5.405400E-01 |
| Stage1-vs-Stage3 |
1.680620E-01 |
| Stage1-vs-Stage4 |
5.304600E-01 |
| Stage2-vs-Stage3 |
7.930200E-01 |
| Stage2-vs-Stage4 |
9.693400E-01 |
| Stage3-vs-Stage4 |
7.458600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.50330000003862E-06 |
| Normal-vs-Asian |
2.53509999659229E-08 |
| Caucasian-vs-AfricanAmerican |
1.745590E-01 |
| Caucasian-vs-Asian |
2.763600E-01 |
| AfricanAmerican-vs-Asian |
6.925400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
7.813700E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
1.17572618307804E-13 |
| Normal-vs-Age(61-80Yrs) |
1.70929936871289E-12 |
| Normal-vs-Age(81-100Yrs) |
2.357700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.438590E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.722800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.320400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.484200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.214000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.569000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.719200E-01 |
| Classical-VS-Follicular |
1.577040E-01 |
| Classical-VS-Other |
7.039800E-02 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
1.425240E-01 |
| Tall-VS-Other |
7.048400E-02 |
| Tall-VS-Normal |
9.77450000050339E-07 |
| Follicular-VS-Other |
3.255400E-01 |
| Follicular-VS-Normal |
1.85385040651909E-12 |
| Other-VS-Normal |
1.20380000001585E-06 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
6.51700915454967E-13 |
| N0-vs-N1 |
6.593000E-01 |
|
|
